Abstract: Methods for making synthetic stone items from industrial wastes are disclosed. Industrial wastes such as waste to energy ash are used as binders, which when mixed with activators, act as substitutes for Ordinary Portland Cement (OPC), with the same uses of OPC, to make concrete and other synthetic stone items. Methods are disclosed for seeding the industrial wastes with zeolite nuclei, allowing initial zeolite formation, and then arresting the zeolite formation, plus seeding those industrial wastes with porosity components. Then upon mixing with activators, these seeded binders result in synthetic stones with porosity and with distributed arrested zeolites all of which aid self-healing of the synthetic stone and in the permanent capture of atmospheric impurities.

Abstract: A chimeric antigen receptor (CAR), a cell (particularly an immune cell such as a regulatory T cell) expressing said CAR, a nucleic acid or vector encoding said CAR and various uses of said CAR, cell, nucleic acid or vector is disclosed herein. Particularly, a chimeric antigen receptor (CAR) comprising an antigen recognition domain that specifically binds to ENTPD3, is provided.

Abstract: The present invention is related to antibodies and antigen-binding fragments of antibodies that specifically bind the SARS-CoV-2 glycoprotein S (spike) as well as diagnostic and therapeutic methods of using those antibodies.

Abstract: Methods for engineered mesoporous cellular magmatics and articles thereof are disclosed. For example, the magmatics may include a mixture of substance that, when exposed to heat for a length of time, form a foamed mass. The foamed mass may be exposed to a solution configured to cause mineralization upon and within the articles.

Abstract: The present invention relates to human tissue kallikrein 7 (KLK7) selective inhibitor compounds, combinations including these compounds, process to obtain the referred compounds, and methods of using the same. The present invention belongs to the field of chemistry, pharmacology and medicine.

Abstract: Methods for engineered mesoporous cellular magmatics and articles thereof are disclosed. For example, the magmatics may include a mixture of substance that, when exposed to heat for a length of time, form a foamed mass. The foamed mass may be exposed to a solution configured to cause mineralization upon and within the articles.

Abstract: The invention provides an optimized and far potent chimeric antigen receptor for its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the hosts immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 in a recipient patient who is negative for HLA-A*02, i.e. the patient prior to transplantation does not express HLA-A*02. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

Abstract: The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Abstract: Methods for engineered cellular magmatics usable for remediation and catalytic applications and articles thereof are disclosed. For example, the magmatics may include one or more infiltration materials that are configured not to sinter when a foamed mass is formed. The infiltration materials may be enclosed in cells of the foamed mass and may be floating and/or fixed to the cell walls.

Abstract: Methods for engineered cellular magmatic usable as filter media and articles thereof are disclosed. For example, the magmatics may include one or more infiltration materials that are configured not to sinter when a foamed mass is formed. The infiltration materials may be enclosed in cells of the foamed mass and may be floating and/or fixed to the cell walls.

Abstract: Described herein are methods for producing multiple disinfecting agents from oils and reactors for producing multiple disinfecting agents from oils.

Abstract: Described herein are methods for producing multiple disinfecting agents from oils and reactors for producing multiple disinfecting agents from oils. Further described herein are methods and reactors for creating a safe antimicrobial barrier on surfaces.

Abstract: Described herein are methods for producing multiple disinfecting agents from oils, including waste oils, and reactors for producing multiple disinfecting agents from the oils.

Abstract: Methods for engineered cellular magmatic microbial habitat and articles thereof are disclosed. For example, the magmatics may include one or more infiltration materials that are configured not to sinter when a foamed mass is formed. The infiltration materials may be enclosed in cells of the foamed mass and may be floating and/or fixed to the cell walls.

Abstract: Methods for engineered cellular magmatic geotechnical fill and articles thereof are disclosed. For example, the magmatics may include one or more infiltration materials that are configured not to sinter when a foamed mass is formed. The infiltration materials may be enclosed in cells of the foamed mass and may be floating and/or fixed to the cell walls.

Abstract: A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

Abstract: A fusion protein for use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A*02 or SLA-01*0401 in a recipient patient who is negative for HLA-A*02 or SLA-01*0401, i.e. the patient prior to transplantation does not express HLA-A*02 or SLA-01*0401. The fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02 or SLA-01*0401.

Abstract: Methods for engineered mesoporous cellular magmatics and articles thereof are disclosed. For example, the magmatics may include a mixture of substance that, when exposed to heat for a length of time, form a foamed mass. The foamed mass may be exposed to a solution configured to cause mineralization upon and within the articles.

Abstract: Methods for engineered mesoporous cellular magmatics and articles thereof are disclosed. For example, the magmatics may include one or more infiltration materials that are configured not to sinter when a foamed mass is formed. The infiltration materials may be enclosed in cells of the foamed mass and may be floating and/or fixed to the cell walls.

Abstract: Methods for engineered polyphase cellular magmatics and articles thereof are disclosed. For example, the magmatics may include multiple phases including a crystalline phase and an amorphous phase. The magmatics may also include one or more reactive agents that may be disposed within cell structures of the magmatics and/or on an exterior of the magmatics, giving the resulting magmatics reactive properties that may differ based on the selected reactive agents and/or placement of the reactive agents within and/or through the magmatics.